# Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation

Study · id `cardio:ct-nct03749057` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03749057](<https://clinicaltrials.gov/study/NCT03749057>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03749057

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.

## Technical summary

Registry record NCT03749057. Allocation not applicable; no masking; primary purpose treatment. Start 2018-11-20 (actual); primary completion 2025-03-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 400 participants (enrolled count; ClinicalTrials.gov record NCT03749057, source copy `cardio:ctgov-nct03749057-2025-08-21`, retrieved 2026-10-26)
- Started: 2018-11-20 (actual) (ClinicalTrials.gov record NCT03749057, source copy `cardio:ctgov-nct03749057-2025-08-21`, retrieved 2026-10-26)
- Primary completion: 2025-03-30 (actual) (ClinicalTrials.gov record NCT03749057, source copy `cardio:ctgov-nct03749057-2025-08-21`, retrieved 2026-10-26)
- Completion: 2025-03-30 (actual) (ClinicalTrials.gov record NCT03749057, source copy `cardio:ctgov-nct03749057-2025-08-21`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03749057, source copy `cardio:ctgov-nct03749057-2025-08-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03749057-2025-08-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation
- Acronym: ERSAF
- Condition: Cerebral Infarction
- Condition: TIA
- Intervention (Drug): Rivaroxaban
- Lead sponsor: General Hospital of Shenyang Military Region
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: General Hospital of Shenyang Military Region (`cardio:org-general-hospital-of-shenyang-military-region`)

## Provenance

Content hash: 9034bbf340dfa35740b49ac8e812c0a94ac9a798435c2744642918fad760f9f0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
